Manuel González-Ortiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Manuel González-Ortiz has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Esperanza Martínez-Abundis
Departamento de Fisiología, Instituto de Terapéutica Experimental y Clínica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara
27 shared publicationsE Martínez-Abundis
6 shared publicationsE. Martínez-Abundis
West National Medical Center Mexican Institute of Social Security
5 shared publicationsJosé A. Robles-Cervantes
Medical Research Unit in Clinical Epidemiology, Specialties Hospital, Medical Unit of High Specialty, West National Medical Center, Mexican Institute of Social Security, Guadalajara, Mexico
5 shared publicationsMaria G. Ramos-Zavala
Specialties Hospital
5 shared publicationsAlejandra M. Ramírez-Rodríguez
Institute of Experimental and Clinical Therapeutics, Department of Physiology, Health Sciences University Center, University of Guadalajara, Guadalajara, Jalisco, Mexico
4 shared publications
Latest Publications
- 1 December 2023
- Published by IMR Press in International Journal for Vitamin and Nutrition Research
- Vol. 93 (6) , 498-506
Anti-hyperglycemic effects of propolis or metformin in type 2 diabetes mellitus
Background: The aim of this study was to evaluate the effect of propolis or metformin versus placebo on glycemic control in pharmacological treatment-naïve patients with type 2 diabetes mellitus (T2DM). Methods: A double-blind, randomized, placebo-controlled in parallel groups clinical trial was performed in 36 pharmacological treatment-naïve patients with T2DM. They received propolis (300 mg), metformin (850 mg), or placebo twice daily before breakfast and dinner for 12 weeks. At the beginning and end of the study, fasting plasma glucose (FPG), 2-h postload glucose (2-h PG) during a 75-g oral glucose tolerance test, glycated hemoglobin A1c (A1C) and a metabolic profile were measured. Areas under the curve (AUC) of glucose and insulin, total insulin secretion (insulinogenic index), the first phase of insulin secretion (Stumvoll index), and insulin sensitivity (Matsuda index) were calculated. Statistical analyses: Kruskal-Wallis, Mann-Whitney U and Wilcoxon tests. Results: The propolis and metformin groups exhibited significant reductions in FPG (p=0.009 and p=0.001, respectively), 2-h PG (p=0.034 and p=0.001, respectively) levels, AUC of insulin, Stumvoll index, and an increment in the Matsuda index. The comparison of the changes from baseline to the end showed significant differences between placebo and propolis in FPG (p=0.004) and A1C (p=0.049) levels, while between placebo and metformin were in FPG (p=0.002), 2-h PG (p=0.004) and A1C (p=0.007) levels. Conclusions: The administration of propolis and metformin compared to placebo reduced FPG and A1C levels; in addition, metformin decreased 2-h PG, AUC of glucose and insulin, high-density lipoprotein cholesterol, and increased the insulin sensitivity.
- 1 December 2023
- Published by IMR Press in International Journal for Vitamin and Nutrition Research
- Vol. 93 (6) , 498-506
Anti-hyperglycemic effects of propolis or metformin in type 2 diabetes mellitus
Background: The aim of this study was to evaluate the effect of propolis or metformin versus placebo on glycemic control in pharmacological treatment-naïve patients with type 2 diabetes mellitus (T2DM). Methods: A double-blind, randomized, placebo-controlled in parallel groups clinical trial was performed in 36 pharmacological treatment-naïve patients with T2DM. They received propolis (300 mg), metformin (850 mg), or placebo twice daily before breakfast and dinner for 12 weeks. At the beginning and end of the study, fasting plasma glucose (FPG), 2-h postload glucose (2-h PG) during a 75-g oral glucose tolerance test, glycated hemoglobin A1c (A1C) and a metabolic profile were measured. Areas under the curve (AUC) of glucose and insulin, total insulin secretion (insulinogenic index), the first phase of insulin secretion (Stumvoll index), and insulin sensitivity (Matsuda index) were calculated. Statistical analyses: Kruskal-Wallis, Mann-Whitney U and Wilcoxon tests. Results: The propolis and metformin groups exhibited significant reductions in FPG (p=0.009 and p=0.001, respectively), 2-h PG (p=0.034 and p=0.001, respectively) levels, AUC of insulin, Stumvoll index, and an increment in the Matsuda index. The comparison of the changes from baseline to the end showed significant differences between placebo and propolis in FPG (p=0.004) and A1C (p=0.049) levels, while between placebo and metformin were in FPG (p=0.002), 2-h PG (p=0.004) and A1C (p=0.007) levels. Conclusions: The administration of propolis and metformin compared to placebo reduced FPG and A1C levels; in addition, metformin decreased 2-h PG, AUC of glucose and insulin, high-density lipoprotein cholesterol, and increased the insulin sensitivity.
- Open Access
- 28 September 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5741
Ellagic Acid Effect on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors, usually with a common pathophysiological origin in insulin resistance and abdominal obesity. Considering the reported effects of ellagic acid (EA) on insulin resistance and abdominal obesity, the aim of this study was to evaluate the effect of EA on the components of MetS, insulin sensitivity and insulin secretion by conducting a randomized, double-blind, placebo-controlled, clinical trial with 32 volunteers diagnosed with MetS. Sixteen patients were randomly allocated, received 500 mg of EA orally twice a day for 12 weeks, and the other 16 received a placebo. Clinical and laboratory determinations were obtained at baseline and at the end of the study. After EA administration, patients reduced their waist circumference (females: 102.2 ± 4.2 to 99.5 ± 3.2 cm (p < 0.05); males: 99.8 ± 6.7 to 96.0 ± 4.7 cm (p < 0.01)), systolic blood pressure (118.1 ± 10.1 to 113.7 ± 7.8 mmHg (p < 0.01)), diastolic blood pressure (118.1 ± 10.1 to 113.7 ± 7.8 mmHg (p < 0.01)), triglycerides (2.8 ± 1.1 to 2.1 ± 0.7 mmol/L (p < 0.01)), fasting plasma glucose (6.5 ± 0.5 to 5.7 ± 0.6 mmol/L (p < 0.01)), fasting plasma insulin (p < 0.01), and insulin secretion (p < 0.05), with an increase of insulin sensitivity (p < 0.01). In male patients, high-density lipoprotein cholesterol increased (p < 0.05). In conclusion, EA improved the components of MetS, reduced hyperinsulinemia, and improved insulin sensitivity.
- 28 September 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5741
Open AccessEllagic Acid Effect on the Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors, usually with a common pathophysiological origin in insulin resistance and abdominal obesity. Considering the reported effects of ellagic acid (EA) on insulin resistance and abdominal obesity, the aim of this study was to evaluate the effect of EA on the components of MetS, insulin sensitivity and insulin secretion by conducting a randomized, double-blind, placebo-controlled, clinical trial with 32 volunteers diagnosed with MetS. Sixteen patients were randomly allocated, received 500 mg of EA orally twice a day for 12 weeks, and the other 16 received a placebo. Clinical and laboratory determinations were obtained at baseline and at the end of the study. After EA administration, patients reduced their waist circumference (females: 102.2 ± 4.2 to 99.5 ± 3.2 cm (p < 0.05); males: 99.8 ± 6.7 to 96.0 ± 4.7 cm (p < 0.01)), systolic blood pressure (118.1 ± 10.1 to 113.7 ± 7.8 mmHg (p < 0.01)), diastolic blood pressure (118.1 ± 10.1 to 113.7 ± 7.8 mmHg (p < 0.01)), triglycerides (2.8 ± 1.1 to 2.1 ± 0.7 mmol/L (p < 0.01)), fasting plasma glucose (6.5 ± 0.5 to 5.7 ± 0.6 mmol/L (p < 0.01)), fasting plasma insulin (p < 0.01), and insulin secretion (p < 0.05), with an increase of insulin sensitivity (p < 0.01). In male patients, high-density lipoprotein cholesterol increased (p < 0.05). In conclusion, EA improved the components of MetS, reduced hyperinsulinemia, and improved insulin sensitivity.
- 1 June 2021
- Published by Wolters Kluwer Health in Blood Pressure Monitoring
- Vol. 26 (3) , 243
Response to Comment on Díaz-Cruz et al. Effect of dapagliflozin on blood pressure variability in patients with prediabetes and prehypertension without pharmacological treatment: a randomized trial Blood Press Monit 2020; 25:346-350
- 1 June 2021
- Published by Wolters Kluwer Health in Blood Pressure Monitoring
- Vol. 26 (3) , 243
Response to Comment on Díaz-Cruz et al. Effect of dapagliflozin on blood pressure variability in patients with prediabetes and prehypertension without pharmacological treatment: a randomized trial Blood Press Monit 2020; 25:346-350
- 17 August 2020
- Published by Wolters Kluwer Health in Blood Pressure Monitoring
- Vol. 25 (6) , 346-350
Effects of dapagliflozin on blood pressure variability in patients with prediabetes and prehypertension without pharmacological treatment: a randomized trial
Aim: The aim of the study was to evaluate the effect of dapagliflozin on blood pressure variability (BPV) in patients with prediabetes and prehypertension without pharmacological treatment. Methods: A double-blind, randomized, placebo-controlled clinical study was performed in 30 patients (30–60 years) diagnosed with prediabetes and prehypertension. Study subjects were divided into two groups: a 10-mg dose of dapagliflozin was administered daily before breakfast for 12 weeks in 15 patients or placebo in the remaining 15 patients. At the beginning and end of the study, clinical and metabolic evaluations were performed, and the 24-h BPV was calculated. Results: Dapagliflozin significantly decreased body weight (P = 0.010), BMI (P = 0.011), fasting plasma glucose (P = 0.002), glycated hemoglobin A1c (P = 0.004), office systolic blood pressure (SBP) (P = 0.001), office diastolic blood pressure (DBP) (P = 0.011), 24-h SBP (121 ± 8 vs. 117 ± 11 mmHg, P = 0.046), nighttime SBP (114 ± 11 vs. 108 ± 10 mmHg, P = 0.017), nocturnal mean arterial pressure (P = 0.043), and nocturnal hypertensive load (P = 0.015); and it significantly increased the percentage of the dipper circadian BP pattern (16.7 vs. 30.8%, P = 0.047). After the administration of dapagliflozin, some of the patients did not meet the diagnostic criteria for prediabetes (26.9%) or prehypertension (26.9%). Conclusions: The administration of 10 mg dapagliflozin once daily for 90 days in patients with prediabetes and prehypertension decreased BPV by reducing 24-h and nighttime SBP, and increasing the dipper circadian BP pattern.
- 17 August 2020
- Published by Wolters Kluwer Health in Blood Pressure Monitoring
- Vol. 25 (6) , 346-350
Effects of dapagliflozin on blood pressure variability in patients with prediabetes and prehypertension without pharmacological treatment: a randomized trial
Aim: The aim of the study was to evaluate the effect of dapagliflozin on blood pressure variability (BPV) in patients with prediabetes and prehypertension without pharmacological treatment. Methods: A double-blind, randomized, placebo-controlled clinical study was performed in 30 patients (30–60 years) diagnosed with prediabetes and prehypertension. Study subjects were divided into two groups: a 10-mg dose of dapagliflozin was administered daily before breakfast for 12 weeks in 15 patients or placebo in the remaining 15 patients. At the beginning and end of the study, clinical and metabolic evaluations were performed, and the 24-h BPV was calculated. Results: Dapagliflozin significantly decreased body weight (P = 0.010), BMI (P = 0.011), fasting plasma glucose (P = 0.002), glycated hemoglobin A1c (P = 0.004), office systolic blood pressure (SBP) (P = 0.001), office diastolic blood pressure (DBP) (P = 0.011), 24-h SBP (121 ± 8 vs. 117 ± 11 mmHg, P = 0.046), nighttime SBP (114 ± 11 vs. 108 ± 10 mmHg, P = 0.017), nocturnal mean arterial pressure (P = 0.043), and nocturnal hypertensive load (P = 0.015); and it significantly increased the percentage of the dipper circadian BP pattern (16.7 vs. 30.8%, P = 0.047). After the administration of dapagliflozin, some of the patients did not meet the diagnostic criteria for prediabetes (26.9%) or prehypertension (26.9%). Conclusions: The administration of 10 mg dapagliflozin once daily for 90 days in patients with prediabetes and prehypertension decreased BPV by reducing 24-h and nighttime SBP, and increasing the dipper circadian BP pattern.
- 27 August 2018
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 128 (08) , 506-511
Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients with Prediabetes
Aim To evaluate the effect of dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes. Methods A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 adults diagnosed with prediabetes and without pharmacological treatment. Patients were randomly assigned into two groups of 12 patients each to receive 10 mg of oral dapagliflozin or placebo once a day during 12 weeks. At baseline and at the end of the study, anthropometric and metabolic measurements were evaluated, including the first phase of insulin secretion, total insulin secretion, and insulin sensitivity. Results After dapagliflozin administration, there were significant decreases in body weight (80.8±16.3 vs. 77.8±14.9 kg, p=0.019), body mass index (30.3±3.5 vs. 29.2±3.1 kg/m2, p=0.023), waist circumference (100.6±13.5 vs. 96.2±11.8 cm, p=0.003), fasting glucose (5.9±0.4 vs. 5.1±0.3 mmol/L, p<0.001) and uric acid (334.3±70.8 vs. 262.9±60.7 mmol/L, p=0.032), with a tendency to increase the insulin sensitivity (1.94±0.72 vs. 2.63±1.04, p=0.064). Conclusion Dapagliflozin administration in patients with prediabetes decreased body weight, body mass index, waist circumference, fasting glucose, and uric acid, with a tendency to increase the insulin sensitivity without changes in insulin secretion.
- 27 August 2018
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 128 (08) , 506-511
Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients with Prediabetes
Aim To evaluate the effect of dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes. Methods A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 adults diagnosed with prediabetes and without pharmacological treatment. Patients were randomly assigned into two groups of 12 patients each to receive 10 mg of oral dapagliflozin or placebo once a day during 12 weeks. At baseline and at the end of the study, anthropometric and metabolic measurements were evaluated, including the first phase of insulin secretion, total insulin secretion, and insulin sensitivity. Results After dapagliflozin administration, there were significant decreases in body weight (80.8±16.3 vs. 77.8±14.9 kg, p=0.019), body mass index (30.3±3.5 vs. 29.2±3.1 kg/m2, p=0.023), waist circumference (100.6±13.5 vs. 96.2±11.8 cm, p=0.003), fasting glucose (5.9±0.4 vs. 5.1±0.3 mmol/L, p<0.001) and uric acid (334.3±70.8 vs. 262.9±60.7 mmol/L, p=0.032), with a tendency to increase the insulin sensitivity (1.94±0.72 vs. 2.63±1.04, p=0.064). Conclusion Dapagliflozin administration in patients with prediabetes decreased body weight, body mass index, waist circumference, fasting glucose, and uric acid, with a tendency to increase the insulin sensitivity without changes in insulin secretion.
- 1 July 2018
- Published by Edizioni Minerva Medica in Minerva Endocrinology
- Vol. 43 (3) , 229-235
Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion
Article: Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion - Minerva Endocrinologica 2018 September;43(3):229-35 - Minerva Medica - Journals
- 1 July 2018
- Published by Edizioni Minerva Medica in Minerva Endocrinology
- Vol. 43 (3) , 229-235
Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion
Article: Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion - Minerva Endocrinologica 2018 September;43(3):229-35 - Minerva Medica - Journals
- 1 December 2017
- Published by Edizioni Minerva Medica in Gazzetta Medica Italiana Archivio per le Scienze Mediche
- Vol. 177 (1-2) , 8-13
Frequency of gestational diabetes mellitus and its association with risk factors in Mexico
Article: Frequency of gestational diabetes mellitus and its association with risk factors in Mexico - Gazzetta Medica Italiana Archivio per le Scienze Mediche 2018 January-February;177(1-2):8-13 - Minerva Medica - Journals
- 1 December 2017
- Published by Edizioni Minerva Medica in Gazzetta Medica Italiana Archivio per le Scienze Mediche
- Vol. 177 (1-2) , 8-13
Frequency of gestational diabetes mellitus and its association with risk factors in Mexico
Article: Frequency of gestational diabetes mellitus and its association with risk factors in Mexico - Gazzetta Medica Italiana Archivio per le Scienze Mediche 2018 January-February;177(1-2):8-13 - Minerva Medica - Journals
- 1 September 2017
- Published by SAGE Publications in Journal of Medicinal Food
- Vol. 20 (9) , 882-886
Effect of Ursolic Acid on Metabolic Syndrome, Insulin Sensitivity, and Inflammation
To evaluate the effect of ursolic acid on metabolic syndrome, insulin sensitivity, and inflammation. A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 patients (30–60 years) with a diagnosis of metabolic syndrome without treatment. They were randomly assigned to two groups of 12 patients, each to receive orally 150 mg of ursolic acid or homologated placebo once a day for 12 weeks. Before and after the intervention, the components of metabolic syndrome, insulin sensitivity (Matsuda index), and inflammation profile (interleukin-6 and C-reactive protein) were evaluated. After ursolic acid administration, the remission of metabolic syndrome occurred in 50% of patients (P = .005) with significant differences in body weight (75.7 ± 11.5 vs. 71 ± 11 kg, P = .002), body mass index (BMI) (29.9 + 3.6 vs. 24.9 ± 1.2 kg/m2, P = .049), waist circumference (93 ± 8.9 vs. 83 + 8.6 cm, P = .008), fasting glucose (6.0 ± 0.5 vs. 4.7 ± 0.4 mmol/L, P = .002), and insulin sensitivity (3.1 ± 1.1 vs. 4.2 ± 1.2, P = .003). Ursolic acid administration leads to transient remission of metabolic syndrome, reducing body weight, BMI, waist circumference and fasting glucose, as well as increasing insulin sensitivity.
- 1 September 2017
- Published by SAGE Publications in Journal of Medicinal Food
- Vol. 20 (9) , 882-886
Effect of Ursolic Acid on Metabolic Syndrome, Insulin Sensitivity, and Inflammation
To evaluate the effect of ursolic acid on metabolic syndrome, insulin sensitivity, and inflammation. A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 patients (30–60 years) with a diagnosis of metabolic syndrome without treatment. They were randomly assigned to two groups of 12 patients, each to receive orally 150 mg of ursolic acid or homologated placebo once a day for 12 weeks. Before and after the intervention, the components of metabolic syndrome, insulin sensitivity (Matsuda index), and inflammation profile (interleukin-6 and C-reactive protein) were evaluated. After ursolic acid administration, the remission of metabolic syndrome occurred in 50% of patients (P = .005) with significant differences in body weight (75.7 ± 11.5 vs. 71 ± 11 kg, P = .002), body mass index (BMI) (29.9 + 3.6 vs. 24.9 ± 1.2 kg/m2, P = .049), waist circumference (93 ± 8.9 vs. 83 + 8.6 cm, P = .008), fasting glucose (6.0 ± 0.5 vs. 4.7 ± 0.4 mmol/L, P = .002), and insulin sensitivity (3.1 ± 1.1 vs. 4.2 ± 1.2, P = .003). Ursolic acid administration leads to transient remission of metabolic syndrome, reducing body weight, BMI, waist circumference and fasting glucose, as well as increasing insulin sensitivity.
- 1 June 2017
- Published by Edizioni Minerva Medica in Minerva Medica
- Vol. 108 (4) , 384-386
Dapagliflozin administration on visceral adiposity, blood pressure and aortic central pressure in overweight patients without type 2 diabetes
Article: Dapagliflozin administration on visceral adiposity, blood pressure and aortic central pressure in overweight patients without type 2 diabetes - Minerva Medica 2017 August;108(4):384-6 - Minerva Medica - Journals
- 1 June 2017
- Published by Edizioni Minerva Medica in Minerva Medica
- Vol. 108 (4) , 384-386
Dapagliflozin administration on visceral adiposity, blood pressure and aortic central pressure in overweight patients without type 2 diabetes
Article: Dapagliflozin administration on visceral adiposity, blood pressure and aortic central pressure in overweight patients without type 2 diabetes - Minerva Medica 2017 August;108(4):384-6 - Minerva Medica - Journals
- 28 February 2017
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 72 (5) , 326-330
Effect of tadalafil administration on insulin secretion and insulin sensitivity in obese men
Aim: To evaluate the effect of tadalafil administration on insulin secretion and insulin sensitivity in obese men without diabetes. Methods: A randomized, double-blind, placebo-controlled clinical trial was carried out in obese male patients between 30 and 50years of age. Eighteen subjects were randomly assigned to two groups of nine patients each. During a 28-day period, subjects received 5mg orally of tadalafil or placebo each night. Patients were evaluated before and after the intervention. Total insulin secretion and first phase of insulin secretion were calculated by insulinogenic index and Stumvoll index, respectively, and insulin sensitivity was calculated using the Matsuda index. Tolerability and compliance were evaluated permanently throughout the study. Results: There were no significant differences after administration of tadalafil in total insulin secretion (0.820.45 vs. 0.61 +/- 0.27, p=0.594), first phase of insulin secretion (1332 +/- 487 vs. 1602 +/- 800, p=0.779) and insulin sensitivity (4.6 +/- 1.2 vs. 4.9 +/- 2.5, p=0.779). No significant differences were shown in other measurements. Conclusion: Tadalafil administration for 28days did not modify insulin secretion or insulin sensitivity in obese men.
- 28 February 2017
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 72 (5) , 326-330
Effect of tadalafil administration on insulin secretion and insulin sensitivity in obese men
Aim: To evaluate the effect of tadalafil administration on insulin secretion and insulin sensitivity in obese men without diabetes. Methods: A randomized, double-blind, placebo-controlled clinical trial was carried out in obese male patients between 30 and 50years of age. Eighteen subjects were randomly assigned to two groups of nine patients each. During a 28-day period, subjects received 5mg orally of tadalafil or placebo each night. Patients were evaluated before and after the intervention. Total insulin secretion and first phase of insulin secretion were calculated by insulinogenic index and Stumvoll index, respectively, and insulin sensitivity was calculated using the Matsuda index. Tolerability and compliance were evaluated permanently throughout the study. Results: There were no significant differences after administration of tadalafil in total insulin secretion (0.820.45 vs. 0.61 +/- 0.27, p=0.594), first phase of insulin secretion (1332 +/- 487 vs. 1602 +/- 800, p=0.779) and insulin sensitivity (4.6 +/- 1.2 vs. 4.9 +/- 2.5, p=0.779). No significant differences were shown in other measurements. Conclusion: Tadalafil administration for 28days did not modify insulin secretion or insulin sensitivity in obese men.